Loading…
Loading…
NOVI, Mich., July 20, 2026 (GLOBE NEWSWIRE) -- Gentherm, a global market leader of innovative thermal management and pneumatic comfort technologies, announced today it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System.
Gentherm (THRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NOVI, Mich., July 07, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, will report its financial results for the second quarter 2026 on Thursday, July 23, 2026, and will host a conference call to discuss those results at 8 am (ET) that same day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Company Announces Shares for Debt Settlements Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units.
Gentherm Incorporated remains a soft Buy as its transformation and merger with Modine Performance Technologies drive significant upside potential. THRM delivered impressive Q1 FY2026 results: sales up 11.2% to $393.7M, outpacing a contracting vehicle production market. Management guides for FY2026 revenue of $1.5–$1.6B and EBITDA of $175–$195M, with the Modine merger expected to boost combined revenue to $2.6B and EBITDA to $322M.
The market consistently misprices the physical infrastructure required to sustain exponential technological growth. Right now, the structural bottleneck for artificial intelligence (AI) is not silicon availability.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for THRM and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.